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http://dx.doi.org/10.1016/j.ccr.2013.08.001SUMMARYDespite extensive study, few therapeutic targets have been identified for glioblastoma (GBM). Here
we show that patient-derived glioma sphere cultures (GSCs) that resemble either the proneural (PN) or
mesenchymal (MES) transcriptomal subtypes differ significantly in their biological characteristics.
Moreover, we found that a subset of the PN GSCs undergoes differentiation to a MES state in a TNF-a/
NF-kB-dependent manner with an associated enrichment of CD44 subpopulations and radioresistant
phenotypes. We present data to suggest that the tumor microenvironment cell types such as macro-
phages/microglia may play an integral role in this process. We further show that the MES signature,
CD44 expression, and NF-kB activation correlate with poor radiation response and shorter survival in
patients with GBM.Significance
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NFkB Activation and Radiation Resistance in GBMINTRODUCTION
Glioblastoma (GBM) is themost commonmalignant primary cen-
tral nervous system tumor in adults and remains resistant to cur-
rent therapies (Furnari et al., 2007) Ample evidence exists to
argue that GBM, as defined by histopathologic criteria, actually
represents multiple distinct molecular entities (Huse et al.,
2011). GBM can be segregated into subtypes based on gene
expression signatures. Although the precise classifications
have varied in the literature (Cooper et al., 2010; Huse et al.,
2011; Phillips et al., 2006; Verhaak et al., 2010), two subtypes,
termed proneural (PN) and mesenchymal (MES), appear robust
and generally consistent among the classification schemes.
GBMs in the MES subclass are predominantly primary tumors
that arise denovoand, in somestudies, exhibit aworseprognosis
compared toPN tumors (Colman et al., 2010; Pelloski et al., 2005;
Phillips et al., 2006), whichmaybe related to the fact that a subset
of the PN tumors displays mutations in the isocitrate dehydroge-
nase 1 gene (IDH1) as well as the glioma-CpG island methylator
phenotype (G-CIMP), both favorable prognostic factors (Noush-
mehr et al., 2010; Verhaak et al., 2010). Conversely, MES tumors
are G-CIMP, exhibit wild-type (WT) IDH1, and contain alter-
ations in NF1 (Noushmehr et al., 2010; Verhaak et al., 2010).
Although a wealth of data on molecular alterations in GBM
continues to accumulate, the availability of relevant models
that mirror these alterations is limited. Current evidence points
toward the existence of a small fraction of tumor-initiating cells
in the bulk tumor that also exhibit radioresistant properties
(reviewed in Chen et al., 2012). However, the genetic and epige-
netic alterations underlying TICs derived from glioma sphere
cultures (GSCs) are less characterized. Whereas initial studies
identified CD133 as a tumor-initiating marker, CD133 subpop-
ulations that resemble the MES subtype also retain the capacity
to form tumors in orthotopic transplantation models (reviewed in
Stopschinski et al., 2012). Consequently, additional cell surface
antigens have been proposed as tumor-initiating markers for
GSCs including CD44 (Brescia et al., 2012; Jijiwa et al., 2011),
a marker that is enriched in cancer stem cells as well as those
that undergo epithelial to MES transition (EMT; Zo¨ller, 2011).
Interestingly, MES transition has also been shown to occur in
GBM and can be induced by master transcription factors (TFs),
STAT3, C/EBPb, and TAZ (Bhat et al., 2011; Carro et al., 2010).
Whether this transition occurs in a cell-intrinsic manner or can
be influenced by factors secreted in the tumormicroenvironment
is not known. Furthermore, whether MES differentiation leads to
enrichment of the CD44 subpopulation in a fashion similar to
other solid tumors remains unexplored. Finally, PN tumors
have been found to give rise to MES recurrences, suggestive
of a PN to MES transition (Phillips et al., 2006). Therefore, under-
standing the mechanistic basis of MES differentiation may have
implications for the treatment of GBM.
RESULTS
Patient-Derived GSCs Bear Resemblance to PN and
MES Signatures
In the context of molecular subtypes reported for GBM, we
examined whether GSCs isolated from patient-derived tumors
show similar characteristics. Forty-one GBM tumors were sub-332 Cancer Cell 24, 331–346, September 9, 2013 ª2013 Elsevier Incjected to culture conditions according to published protocols
and successful expansion as neurospheres was observed in 33
cases (Table S1 available online). Seventeen GSCs that were
expanded earliest were chosen formicroarray analysis to identify
molecular subtypes using unsupervised algorithms. Using 500
probe sets with the highest variability in gene expression, two
clusters of coexpressed genes were readily apparent by hierar-
chical clustering (Figure 1A). These two clusters for the most
part were well defined, although some GSCs did not readily fit
in this pattern (e.g., GSC6-27, 30, and 46). The primary or recur-
rent status of the parental tumor of origin had no bearing on the
cluster segregation (cluster 1 = 33% versus cluster 2 = 36%
recurrent tumors; Figure 1A). To understand the functional signif-
icance of these two gene clusters, we performed Gene Ontology
(GO) analysis using the Database for Annotation, Visualization
and Integrated Discovery (DAVID) webtool (Dennis et al., 2003).
Cluster 1 GO terms were enriched for wound response, vascula-
ture formation, and cell motility gene signatures (Figure 1B),
whereas cluster 2 showed predominant association with differ-
entiated neural or glial cell functions and homeostatic activities
(Figure 1B). Importantly, cluster 1 showed significant similarity
only to theMESGBM subclass by Gene Set Enrichment Analysis
(GSEA; Subramanian et al., 2005; Figure 1C), with 89 out of the
top 500 enriched genes being MES (Figure S1A; Table S2). Simi-
larly, cluster 2 predominantly comprised PN genes (98/500; Fig-
ures 1C and S1A; Table S2). Supervised clustering using the
TCGA classification (Verhaak et al., 2010) showed a similar
grouping of the GSCs at the first branch of the dendrogram
compared to the unsupervised clustering (Figure S1B). GSC6-
27 and 30 displayed characteristics of both MES and PN gene
signatures. GSC11 and 30 were also enriched for Classical
(CL) signatures. EGFR amplification, usually restricted to the
CL subtype, was seen in 5 out of the 14 GSCs and appeared
distributed between the PN and MES subtypes (3 PN and 2
MES; Figure S1C). NF1 homozygous inactivating mutations
were observed in GSC6-27 (exon 39) and GSC28 (exon 50 and
exon 38; Figure S1D), both GSCs that had MES characteristics
consistent with the TCGA analyses (Verhaak et al., 2010). Quan-
titative RT-PCR (qRT-PCR) and immunoblotting of basal expres-
sion of key PN/MES markers (Table S3) were concordant with
microarray results (Figures S1E and S1F).
To rule out the possibility of nonneoplastic cells being enriched
in the GSC isolation procedure, we tested for loss of heterozy-
gosity (LOH) on chromosome 10q, a frequently deleted region
in adult GBM (Pietsch and Wiestler, 1997), and found LOH in
12 out of the 13 GSCs, confirming their neoplastic origin (Fig-
ure S1G). Implantation of 5 3 105 or fewer unsorted GSCs
caused formation of high-grade gliomas (HGGs) in a majority
of the cases (13/17) with predominant histologic features of
this disease (Tables S4 and S5; Figure S1H). A subset of the
tumors exhibited microvascular proliferation and/or pseudopali-
sading necrosis, both hallmarks of GBM (Figure S1H). Thus,
despite differential gene expression signatures, GSCs formed
tumors that were histologically similar.
GSCs Differ in the Transcriptome and Epigenetic
Profiles When Compared to the Originating Tumor
Next, we examined whether gene expression patterns observed
in the GSCs and xenografts matched with the respective.
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Figure 1. Patient-Derived GSCs Bear Resemblance to PN and MES Signatures
(A) Unsupervised hierarchical analysis of the top 500 highest median absolute deviation genes from expression microarray of 17 GSCs is shown. Expression data
was Z score corrected for display; relatively lower expression is shown in blue and higher expression is shown in red (see color key). Two large clusters, cluster 1
(128 genes) and cluster 2 (102 genes), were identified (shown as black boxes). The vertical black line identifies the first dendrogram splitting of the GSCs. Primary
(P) or recurrent (R) status of the GSCs is indicated.
(B) The top 20 gene ontology (GO) terms associatedwith cluster 1 (left) and cluster 2 (right) from the unsupervisedGSChierarchical cluster analysis are shown.GO
terms are ranked by p value. The black bars show the number of genes that is common between the GO term’s gene set and the respective cluster gene set. The
golden line is the log10 of the p value as determined by DAVID functional analysis.
(C) GSEA enrichment plots of GSC cluster 1 high (top row) and cluster 2 high (bottom row) gene lists versus queried gene lists are shown (see Supplemental
Experimental Procedures for data source). The normalized enrichment scores (NES) and the p values are shown for each plot.
See also Figure S1 and Tables S1, S2, and S3–S5.
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NFkB Activation and Radiation Resistance in GBMparental GBMs from which they were derived. To determine the
association of a sample with either a PN orMES gene expression
signature, we calculated a metagene score for each sampleCausing a set of four PN (DLL3, OLIG2, ASCL1, and NCAM1) and
four MES (YKL40, SERPINE1, TIMP1, and TGFBI) genes, seven
out of the eight of which were subset defining in published datancer Cell 24, 331–346, September 9, 2013 ª2013 Elsevier Inc. 333
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Figure 2. GSCs Differ in the Transcriptome and Epigenetic Profiles when Compared to the Originating Tumor
(A) Heatmap of the predominant signature of initiatingGBM, derivedGSC, and xenograft for 14 samples is shown. A PN andMES qRT-PCR-basedmetagenewas
calculated for each sample and then compared to each other after Z score correction. Green shades represent a predominantly PN signature, red aMES one, and
black a relatively balanced expression of both, as indicated in the figure.
(B) IHC analysis of Nestin, OLIG2, and YKL40 expression in patient-matched GBM and xenografts of GSCs is shown. Scale bar: 50 mm.
(C) Methylight profiling of GBMs and their derivative GSCs for G-CIMP status is shown. Eleven markers were tested for presence of methylation on their
promoters and coded as red if methylated and green if unmethylated. Samples were deduced as G-CIMP if >50% of the loci showed methylation. A GBM and
(legend continued on next page)
Cancer Cell
NFkB Activation and Radiation Resistance in GBM
334 Cancer Cell 24, 331–346, September 9, 2013 ª2013 Elsevier Inc.
Cancer Cell
NFkB Activation and Radiation Resistance in GBMsets (Phillips et al., 2006; Verhaak et al., 2010). Using this
approach, each sample could be ranked according to its meta-
gene score as being predominantly PN or MES. Surprisingly,
we found that most GSCs that arose from MES tumors lost
MES characteristics and exhibited a higher PN metagene (Fig-
ure 2A). GSC20 and GSC28, both of which originated from highly
MES tumors with histological hallmarks of gliosarcoma (Fig-
ureS2A),maintained theirMESstate in culture andas xenografts.
With the exception ofGSC2andGSC17 (which lostMES features
gained in culture), all PN GSCs maintained their PN status when
examined in xenografts. Alterations in growth factor supple-
ments to culture media did not influence gene expression signa-
tures in established GSCs, although neurosphere formation was
dependent on EGF (Figures S2B and S2C). Immunohistochem-
ical (IHC) analysis on xenografts showed absence of the MES
marker YKL40 in GSCs derived fromMES tumors, which instead
acquired the PN marker OLIG2 (Figures 2B and S2D). This
contrast was not observed in the MES GSC20 that retained
YKL40 expression in the xenograft, similar to the parental tumor,
but lacked OLIG2 expression in both (Figure 2B). These findings
imply that the GSC isolation protocol generally favors a loss of
MES and gain of PN features from patient to xenograft.
Given the tight association of the G-CIMP signature with the
PN subtype (Noushmehr et al., 2010), we asked whether PN
GSCs are G-CIMP+. To test this, we used a previously reported
G-CIMP signature panel that shows correlation with array-based
methylation platforms (Noushmehr et al., 2010). Eleven hyper-
methylated gene regions were chosen based on feasibility and
reproducibility in archival tumor-derived DNA and deemed
G-CIMP+ based on percentage loci that were hypermethylated
(>50%). Consistent with a drift toward a PN signature from tumor
to GSC, we observed that PNGSCs were G-CIMP+ compared to
their parental tumors that were G-CIMP (Figures 2C and S2E).
To the contrary, MES GSCs 20 and 28 remained G-CIMP
similar to their parental tumors (Figure 2C). To test for the extent
of similarity to the previously described G-CIMP signature on a
genome-wide scale, we profiled three GSCs using the Illumina
Infinium methylation array (Figure 2D). Upon cross-examination
with TCGA tumors, PN GSCs 11 and 23 segregated with
G-CIMP+ tumors, while GSC20 clustered with the G-CIMP
cases. Overall, GSCs 11 and 23 showed greater hypermethyla-
tion compared to GSC20 (Figure S2F) and showed an 70%
enrichment of G-CIMP signature genes, although numerous
distinct non-G-CIMP loci also appeared hypermethylated in
these GSCs (Figure 2E). Taken together, our data suggest that
PN GSCs can exhibit hypermethylation patterns (henceforth
named CIMP) with similarities to G-CIMP even in the absence
of IDH1 mutations.
Molecular Signatures Differ between GBM and Their
Derivative GSCs Even in Early Passages
Based on our initial findings, two possibilities were considered:
(1) culturing of freshly resected GBMs in serum-free media sup-an anaplastic oligodendroglioma (AOD) sample were used as negative and po
shown below.
(D) Heatmap shows the unsupervised clustering of 1,138 differentially hypermeth
(E) Venn diagram shows the number of hypermethylated probes (b valuesR 0.5
See also Figure S2.
Caplemented with growth factors preferentially induces a PN/
CIMP+ signature in culture, or (2) most undifferentiated GSCs
are innately PN/CIMP+, but the microenvironment in human
tumors induces a reversible MES/CIMP differentiation, which
is not entirely recapitulated in vitro or in xenografts of immuno-
compromised mice. To discern which one of these can be
attributed to a general MES/CIMP to PN/CIMP+ drift, and to
reduce the potential of artifacts from long-term culture, we
examined freshly resected tissues and their derivative serial
passage GSCs for gene expression and methylation signatures
as soon as sufficient starting material was available for ana-
lyses. Strikingly, even in early passages (fewer than five), we
observed that GSCs showed PN characteristics despite having
a MES origin (Figure S2G). Moreover, these early passage
GSCs were CIMP+ in contrast to their parental tumors, which
were CIMP (Figure S2H). These observations, taken together
with previous studies showing requirement of extended pas-
sages for the induction of the G-CIMP phenotype by IDH1
mutation (Lu et al., 2012; Turcan et al., 2012), favor a model
in which a majority of undifferentiated GSCs already exist in a
PN/CIMP+ state and are selectively enriched under proliferating
conditions.
CD44 Is Enriched in the MES Subtype and Is Inversely
Correlated with OLIG2 Expression
Next, to test whether the differential molecular signatures have
a bearing on their biological properties, we expanded our
repertoire of GSCs. We first examined the expression of cell
surface markers that have been used to define tumor-initiating
potential. We observed enrichment of CD15 specifically in the
PN/CIMP+ subclass of GSCs (e.g., GSC11, GSC23, and
GSC34) that also expressed equal or smaller percentages of
CD44 (Figure 3A), although the ratio of CD15 to CD44 varied
with passage or confluence of spheres. MES/CIMP GSCs
(e.g., GSC20, GSC28, and GSC2) did not express appreciable
levels of CD15 but predominantly expressed CD44 (Figure 3A).
Comparison of CD15 and CD44 expression among GSCs with a
range of passage times showed no correlation (Figures S3A
and S3B). Using OLIG2 as a surrogate for CD15 (Figure S3C)
as previously shown (Son et al., 2009), we found a mutually
exclusive pattern of inter- and intratumoral staining with CD44
(Figures 3B, 3C, and S3D), implying that these were indeed
distinct tumor populations. Furthermore, PN tumors expressed
higher levels of OLIG2 whereas MES tumors predominantly
expressed CD44 and the expression of OLIG2 and CD44
was inversely correlated (Figures 3D and S3E). Additionally,
CD44high subpopulations within PN/CIMP+ GSCs showed
enrichment of MES markers (Figure S3F). Thus, whereas un-
sorted GSCs formed tumors upon transplantation irrespective
of exclusive expression of tumor initiation markers, CD15
(e.g., GSC7-11) or CD44 (e.g., GSC20), the proportion of the
cell surface expression of CD44 appeared to correlate with a
MES state.sitive controls, respectively. The IDH1 and G-CIMP status of all samples is
ylated probes from the G-CIMP signature.
) in GSCs 11, 23, and TCGA G-CIMP+ tumors.
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Figure 3. CD44 Is Enriched in the MES Sub-
type and Is Inversely Correlated with OLIG2
Expression
(A) CD15 and CD44 of various GSCs were deter-
mined by flow cytometry. Bar graph indicates
percentage of viable cells that express these
markers at the earliest passage tested. ND, not
determined.
(B) Immunofluorescent staining of OLIG2 (green)
and CD44 (red) in human GBM tumors shows a
mutually exclusive pattern of staining. Scale bar:
20 mm. The merged image of CD44/OLIG2 is
shown on the right against 40,6-diamidino-2-phe-
nylindole (DAPI)-stained nuclei (blue). Enlarged
inset is shown in the lower panel (scale bar: 20 mm).
Quantification of staining in three random fields of
three independent tumors and the p value from
chi-square test are shown on the right.
(C) Representative IHC images of OLIG2 andCD44
expression in human GBM samples are shown.
Scale bar: 50 mm. The table to the right shows
the number of tumors expressing OLIG2/CD44.
Tumors were classified as low/negative, interme-
diate, or high depending on the extent of expres-
sion in the overall tumors. p value was calculated
using chi-square test.
(D) Box plots show the normalized median
expression of OLIG2 and CD44 in TCGA tumors
based on Phillips and TCGA classification. Boxes
show median 25th and 75th percentiles, while
whiskers show the 5th and the 95th percentiles. The
p value was determined using a nonparametric
Wilcoxon test.
See also Figure S3.
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NFkB Activation and Radiation Resistance in GBMPN/CIMP+ and MES/CIMP– GSCs Display Differential
Sensitivity to Radiation
To test whether GSCs with varied transcriptome, methylation,
and cell surface antigen expression patterns also exhibit differ-
ential treatment responses, we examined the consequence of
clinically relevant fractionated ionizing radiation (IR; 2.5 Gy 3 4)
on mice 2–3 weeks after orthotopic implantation of GSCs. PN/
CIMP+ GSCs (7-11 and 23) showed significantly improved
median survival (5–9 weeks) upon IR treatment, whereas
GSC20 showed no statistical difference and GSC267 showed
modest survival (2 weeks) improvement compared to un-
treated controls (Figure 4A). Because glioma cells predominantly
arrest in the G2/M phase of cell cycle in response to IR (Mir et al.,
2010), we asked whether the two subtypes of GSCs showed
fundamental differences in this mode of arrest. Indeed, PN/
CIMP+ GSCs showed dramatic accumulation of cells in G2/M,
whereas MES/CIMP GSCs showed only a modest arrest (Fig-
ure 4B). In addition, although both subtypes of GSCs showed
comparable g-H2AX foci formation at early time points, MES/336 Cancer Cell 24, 331–346, September 9, 2013 ª2013 Elsevier Inc.CIMP GSCs (2, 20, and 267) showed
enhanced repair ability as evidenced by
the reduced number of foci at 24 hr
compared to PN/CIMP+ GSCs (Fig-
ure 4C), consistent with the lack of
G2/M arrest. Consequently, the PN/
CIMP+ GSCs underwent profoundapoptosis (Figure 4D) with reduced neurosphere formation com-
pared to MES/CIMP GSCs (Figure 4E). We further observed a
similar radioresistant CD44high population within the PN/CIMP+
GSCs (Figures S4A–S4C).
TNF-a Mediates MES Differentiation in an
NF-kB-Dependent Fashion
Despite originating from MES tumors, the lack of MES signature
in xenografts led us to hypothesize that specific factors in the
human tumor microenvironment could alter the transcriptome
and epigenetic signatures of GSCs, but these features are not
entirely recapitulated in immunocompromised mice. In search
of such signaling molecules, we noted that the TCGA analyses
showed specific enrichment of genes in the TNF-a receptor
superfamily and the NF-kB pathway in the MES subclass of
tumors that also expressed high levels of YKL40 and CD44
(Riddick and Fine, 2011; Verhaak et al., 2010). Additionally,
prior studies have shown the association of a hypoxic signature
and the NF-kB pathway to HGGs (Murat et al., 2009). We
Figure 4. PN/CIMP+ and MES/CIMP– GSCs Display Differential Sensitivity to Radiation
(A) Kaplan Meier curves show the survival of mice implanted with PN/CIMP+ (7-11 and 23) or MES/CIMP (20 and 267) GSCs at 53 105 cells per mouse with or
without fractioned intracranial radiation (2.5 Gy 3 4). t test was used to assess statistical significance.
(B) Cell cycle analysis of GSCs treated with 6 Gy IR is shown. The percentage of cells in the G2/M phase is indicated within each cell cycle plot.
(legend continued on next page)
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NFkB Activation and Radiation Resistance in GBMhypothesized that cytokines that can trigger NF-kB or alternative
TF signaling pathways could result in MES differentiation and
influence the proportion of CD44high subpopulations. To test
this, we treated PN/CIMP+ GSCs 11, 23, and 34 with similar con-
centrations of interleukin (IL)-6, IL-8, IL-10, TGF-b, or TNF-a,
all of which are constituents of the GBM microenvironment
(Charles et al., 2011). TNF-a treatment resulted in a dramatic
gain of CD44 expression, an effect not seen with any of the other
cytokines tested (GSC34, Figure 5A; GSC11 and 23, data not
shown), and this effect was blunted by transduction with a
nondegradable mutant form of IkB (IkB superrepressor [IkB-
SR]), indicating an NF-kB-dependent effect (Figure 5B). Interest-
ingly, the CIMP positivity of the GSCs remained unaltered in
response to TNF-a treatment (Figure 5C), implying that the regu-
lation of CIMP can be uncoupled from NF-kB-mediated MES
differentiation in GSCs. However, long-term effects of TNF-a
and/or other potential modifiers of CIMP status are worthy of
further exploration.
To further characterize the extent of MES differentiation, we
performed microarray analysis of GSCs treated with TNF-a
and found significant enrichment of genes involved in wound
healing and vasculature development, as well as the NF-kB
cascade and regulation of cell-death-related genes (Figure 5D),
suggesting that in addition to the canonical NF-kB pathway,
TNF-a induces a parallel MES differentiation in GSCs, which
was further confirmed by qRT-PCR (Figure S5A). Moreover,
genes induced by TNF-a were significantly similar to the GBM
MES subclass (Figure S5B). Interestingly, although a global
reduction of the PN signature was not observed, a significant
downregulation of OLIG2, PDGFRA, and DLL3 transcripts were
seen with TNF-a treatment (data not shown). Physiological con-
centrations (100 pg/ml) of TNF-a were sufficient to cause induc-
tion of YKL40 and CD44 (Figures S5C and S5D), which was
temporally preceded by activation of NF-kB, as judged by serine
536 (ser 536) phosphorylation (Figure S5D). Furthermore, we
identified macrophages/microglia as the stromal cell type that
can potentially induce MES differentiation (Figures S5E–S5I)
and that MES/CIMP GSCs show selective susceptibility to
minocycline, an inhibitor of microglial activation and NF-kB sig-
naling (Figures S5J–S5N; Daginakatte and Gutmann, 2007;
Markovic et al., 2011).
Pretreatment of PN/CIMP+GSCswith TNF-a strongly reduced
the G2/M accumulation in response to IR (Figure 5E) as well as
the number of g-H2AX foci (Figure S5O), and these effects
were inhibited by pretreatment with IkB-SR, indicating that
TNF-a promotes MES differentiation coupled with increased
radioresistance in an NF-kB-dependent manner. We noted that
although long-term treatment of GSCs with TNF-a (5 ng/ml)
reduced the neurosphere formation (Figure S5P), exposure of
GSCs to IR caused significantly higher neurosphere efficiency(C) g-H2AX foci formation assay is shown. Gray bars indicate number of foci after
counted. Error bar indicates ± SEM. t test was used to assess statistical signific
(D) Percentage of cells that were positive for annexin V staining 96 hr post irradiat
population whereas black bars show percentage of annexin-V-positive cells exp
nificance. **p < 0.005; NS, not significant.
(E) Neurosphere formation efficiency was determined by setting the number of s
exposed to 3 Gy IR (black bars). Error bar indicates ± SD. t test was used for sta
See also Figure S4.
338 Cancer Cell 24, 331–346, September 9, 2013 ª2013 Elsevier Incin the presence of TNF-a compared to untreated controls, sug-
gesting a radioprotective effect of TNF-a (Figure S5P). To
examine this in vivo, we expressed firefly luciferase in GSC23
to monitor tumor kinetics using bioluminescent imaging. As ex-
pected, IR caused a strong decrease in tumor volume (Figure 5F),
and a similar growth inhibition was seen with TNF-a treatment
alone, consistent with our in vitro observations. However, a com-
bination of TNF-a and IR caused significant expansion of the
tumor, and the cells appeared similar in volume to the control
group. Overall, our findings indicate that the induction of MES
differentiation and enrichment of CD44 by NF-kB activation pro-
motes radioresistance in PN/CIMP+ GSCs.
NF-kB Controls Master TFs of MES Differentiation
in GSCs
Next, we explored how NF-kB pathway activation integrates into
theMES signaling network and its relation tomaster TFs (STAT3,
C/EBPb, and TAZ) known to induce this signature. We found that
both total and phosphorylated forms of p65 (ser 536) were signif-
icantly higher in MES/CIMP-GSCs 2 and 20 when compared to
PN/CIMP+ GSCs 11 and 23 (Figure 6A). The expression of
STAT3 and C/EBPb as well as phosphorylation at tyrosine 705
of STAT3 (which promotes nuclear translocation and DNA
binding of STAT3) were also higher in the MES/CIMP GSCs
(Figure 6A). Similar increases in MES proteins and master TFs
were seen in the CD44high subpopulation when compared to
those that were CD44low (Figures 6B and 6C). CD44 expression
also positively correlated with STAT3, CEBPB, and TAZ expres-
sion as well as NF-kB pathway activation in human GBMs (Fig-
ure 6D). Although these TFs showed strong association with
the MES signature, classic EMT inducers SNAIL, SLUG, and
TWIST1 were not robustly associated (Figure S6A).
To test whether NF-kB mediates MES reprogramming via
master TFs, we treated GSC11 with TNF-a at various time points
and analyzed the temporal expression of these proteins by west-
ern blotting. TNF-a-induced phosphorylation of p65 preceded
the induction of YKL40, STAT3, C/EBPb, and TAZ, an effect
that was negated by pretreatment with IkB-SR, indicating that
the master TFs act downstream of the NF-kB pathway (Figures
6E and S6B). Furthermore, upregulation of STAT3, CEBPB,
and TAZ mRNA was significantly inhibited by IkB-SR pretreat-
ment (Figures 6F and S6B). Finally, concomitant silencing of
STAT3, C/EBPb, and TAZ caused strong reduction of CD44
and YKL40 induced by TNF-a (Figures 6G and S6B). Taken
together, these data indicate that NF-kBpromotesMESdifferen-
tiation inGSCs via induction ofmaster TFs. Interestingly, GSC13,
which originated from a PN tumor (Figure 1C), did not exhibit
MES differentiation even upon long-term culture in TNF-a, sug-
gesting that some PN GSCs are resistant to NF-kB-mediated
MES differentiation (Figure S2C).6 hr irradiation whereas black bars show foci after 24 hr. At least 25 nuclei were
ant differences. *p < 0.05, **p < 0.005.
ion is shown as bar graphs. Gray bars indicate percentage of cells in untreated
osed to 6 Gy IR. Error bar indicates ± SD. t test was used for statistical sig-
pheres formed in control groups at 100% (gray bars) and compared to those
tistical significance. **p < 0.005.
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Figure 5. TNF-a Mediates MES Differentiation and Radioresistance in an NF-kB-Dependent Fashion
(A) FACS analysis of expression of CD15 and CD44 in GSC34 after 96 hr treatment with 10 ng/ml of indicated cytokines is shown. Percentage of cells in each
quadrant is shown.
(B) Expression of CD15 and CD44 after TNF-a (96 hr, 10 ng/ml) with or without pretreatment with IkB-SR adenovirus or control RFP adenovirus 24 hr prior to
TNF-a treatment by flow cytometry is shown. The stacked bar shows the percentage of CD15/CD44-expressing cells after various treatments.
(C) Methylight profiling of GSCs after 2 weeks of TNF-a treatment is shown.
(D) The top 20 GO terms associated with 1.5-fold or greater TNF-a-induced genes in GSC11 are ranked by lowest p value. Bar graphs show the number of genes
overlapping between the GO category and the query gene list. The golden line is the DAVID functional analysis determined log10 of p values.
(E) Cell cycle analysis of GSCs after treatments is indicated. The percentage of cells in the G2/M phase is indicated within each cell cycle plot.
(F) Tumor volume measurement of GSC23-pCignal lenti-CMV-luc cells injected intracranially into Foxn1nu mice is shown. Mice were imaged 2–3 weeks after
implantation as the first time point (denoted asweek 1), after which the radiation group received four cycles of 2.5 Gy IR on consecutive days.Mice were subject to
(legend continued on next page)
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Are Predictive of Radiation Response in GBM
Because activation of NF-kB caused both MES differentiation
and enrichment of CD44 populations in GSCs, we performed
in-depth analyses of NF-kB activation in GBM. Among previ-
ously annotated direct targets of NF-kB, MES GSCs as well as
tumors (Table S6) showed a 36% enrichment (induced to a
1.5-fold or greater expression) of these targets when compared
to PN counterparts, which showed only a 6% enrichment (Fig-
ure S7A). Seventeen NF-kB target genes appeared commonly
induced in both MES GSCs and GBMs, which included CD44,
proinflammatory cytokines IL1B and IL8, chemokines CCL2
and CXCL5, prostaglandin enzyme cyclooxygenase 2 (COX2),
and the downstream target of TNF-a stimulation TNFAIP3
that has been previously shown to be associated with GBM
(Hjelmeland et al., 2010; Murat et al., 2009). Thus, the MES
phenotype in GSCs and GBM was accompanied by activated
NF-kB signaling, and CD44 is an integral component of this
signature.
We next examined the association of these variables with
radiation response and treatment outcome in a cohort of newly
diagnosed GBM patients (Table S7). We used a previously
defined radiation response scoring criteria (Pelloski et al.,
2005) by comparing the maximal area of enhancement between
the pre- (i.e., within 1month of the start of radiation) and the post-
RT magnetic resonance imaging (MRI; Figure 7A). Examination
of the PN/MES status showed correlation between MES com-
posite metagene (see Supplemental Experimental Procedures
for details) and progression following RT (nonresponders)
whereas a PN composite metagene correlated to patients with
stable or reduced disease following RT, even in patients with
WT IDH1 tumors (Figures 7B and 7C). After adjusting for patient
age (%50 years versus >50 years), IDH1 status (mutant versus
WT), and Karnofsky Performance Status (KPS; %70 versus
>70), only the MES metagene remained a significant predictor
of RT response (Table S8). Patients with a higher MESmetagene
(upper two-thirds of themetagene quartile) also showed reduced
survival irrespective of IDH1 status (Figures 7D and 7E). Next, we
evaluated whether CD44 and OLIG2 expression could be used
as serviceable markers for MES and PN states, respectively.
Patients with higher expression of CD44 showed a striking asso-
ciation with poor response to radiation and lower survival
compared to those with lower CD44, and conversely, patients
with high OLIG2 were more likely to be responders to radiation
and better survivors (Figures 7F–7I; Figures S7B–S7E). Addition-
ally, using an antibody specific for phosphorylated p65 (ser 276),
a transcriptionally active form of NF-kB, as well as its target
COX2 (Figure S7F), we found significant association of the
expression of these proteins to nonresponders compared to
those with a favorable response to radiation (Figures 7J and
7K; Figures S7G and S7H). Whereas intermediate and high
COX2 expression were associated with poor survival (Figures
7L and S7I), p-p65 expression showed a similar trend but did
not reach statistical significance (data not shown).intracranial administration of TNF-a (2 ng/mouse) 72 hr prior to irrradiation and
(photons/s/cm2/sr) with various treatments and time points. Error bar indicates ±
significant.
See also Figure S5.
340 Cancer Cell 24, 331–346, September 9, 2013 ª2013 Elsevier IncFinally, to characterize intratumoral PN to MES transition in
human GBMs, we closely examined the temporal distribution
of multiple markers by IHC on serial paraffin-embedded sections
(Table S9). The expression of these markers ranged from
pockets of negative expression to those with strong positivity.
Importantly, OLIG2low and CD44high areas (MES signature) coin-
cided with p-p65 positivity (Figure 8A; Table S9). The extent of
macrophages/microglia infiltration (as judged by IBA staining)
also correlated with the MES regions. This finding highlights in-
tratumoral PN/MES heterogeneity that correlates with activation
of NF-kB and macrophages/microglial involvement in GBM.
DISCUSSION
Differential Molecular Signatures in GSCs and GBMs
Whereas gene expression profiling of GBM has consistently
shown the PN and MES subtypes, parallel efforts on GSCs
have been limited, and mouse models representative of tran-
scriptome subtypes of GBM are only beginning to emerge
(Chow et al., 2011; Friedmann-Morvinski et al., 2012; Koso
et al., 2012; Liu et al., 2011). In this report, we demonstrate
that with the exception of a few, GSCs in general show gene
expression and epigenetic profile differences from their parental
tumors and that the majority of the GSCs exhibit an overall PN/
CIMP+ signature despite originating from predominantly MES/
CIMP GBMs. Placement of these PN/CIMP+ GSCs in intracra-
nial xenografts did not restore the MES phenotype of the
parental tumor, indicating a potential shortcoming of immuno-
compromised xenograft models to fully recapitulate the human
tumor microenvironment (Magee et al., 2012). We could not
ascertain the CIMP status of the xenografts because of technical
difficulties given the small size of these tumors. Although TNF-a/
NF-kB activation induced MES differentiation, it did not alter
CIMP methylation patterns, suggesting that other tumor micro-
environment-derived cytokines could play a role in this process.
Coupled with recent reports that resetting the epigenome of
GSCs can cause remarkable changes in their malignant behavior
(Stricker et al., 2013), future studies utilizing GSCs as a model
system should take these factors into consideration.
MES Differentiation Is Mediated by NF-kB Induction of
Master TFs
In addition to the identification of a role for NF-kB in inducing the
MES signature, we show that this occurs via the induction of
STAT3, C/EBPb, and TAZ, although it remains to be seen if the
radioresistance mediated by NF-kB is also dependent on these
master TFs. Interestingly, these same TFs (with the exception
of TAZ) play prominent roles in inflammatory response, and
past studies have shown considerable crosstalk between these
TFs. For example, NF-kB promotes an inflammatory response
through secretion of TNF-a, IL-1b, and IL-6, of which IL-6 trig-
gers STAT3 activation (Ben-Neriah and Karin, 2011; Hayden
and Ghosh, 2012). Conversely, studies have shown that nuclear
translocation of NF-kB is dependent on acetylation of NF-kB byonce every 2 weeks thereafter. Horizontal black bar shows average radiance
SEM. t test was used to assess statistical significance. **p < 0.005; NS, not
.
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The interdependency of NF-kB and C/EBPb has also been pre-
viously reported in other studies (Acosta et al., 2008; Kuilman
et al., 2008). While we show that TNF-a can be derived from
macrophages/microglia, it is noteworthy that these cell types
themselves exhibit plasticity and can be polarized to a proinflam-
matory (M1) or anti-inflammatory (M2) phenotype in the brain
microenvironment (Li and Graeber, 2012; Wu et al., 2010).
Because most GBMs arise de novo without prior clinical history
of a lower grade tumor, it is difficult to study tumor evolution in
GBM, that is, whether a MES tumor evolved from an early stage
PN tumor is difficult to ascertain and the characteristics and the
influence of the microenvironment in the early stages of a GBM
are virtually unknown. Here we show evidence for the transcrip-
tomic plasticity of the PN and MES states by IHC analysis of
tumors that had regions of both PN and MES markers and their
correlation to NF-kB activation and infiltration of macrophages/
microglia. Consistent with our findings, recent studies have
shown that the MES subclass of GBMs exhibit a high degree
of necrosis (Cooper et al., 2012) and macrophages/microglial
infiltration (Engler et al., 2012; Li et al., 2012). In addition, tumor
evolutionary dynamics have been shown in a recent report
wherein multiple transcriptome signatures were found within
the same tumor (Sottoriva et al., 2013). We found that in some
cases, MES/CIMP GSCs showed constitutive MES signatures
even in instances where NF1 mutations were not seen (e.g.,
GSCs 2 and 20) and when removed from the microenvironment,
suggesting that cell intrinsic mechanisms that sustain the MES
network also exist.
Association of the MES Signature, CD44, and NF-kB
Signaling with Radiation Resistance
Patients with GBM currently undergo standard treatment con-
sisting of maximal surgical resection, combined radiation and
chemotherapy, and adjuvant chemotherapy with temozolomide
(Furnari et al., 2007; Hegi et al., 2005). Radiation has been a
mainstay of GBM treatment for decades and the exact molecular
mechanisms driving resistance in GBMs is unknown. Our previ-
ous studies have shown that patients with a MES signature
belong to the poor prognosis subclass and are resistant to stan-
dard treatments (Colman et al., 2010) and that PN tumors can
recur in a MES state (Phillips et al., 2006). Here we show that
PN/CIMP+ GSCs under specific conditions can undergo MES
differentiation, with associated radioresistance. Importantly,Figure 6. NF-kB Controls Master TFs of MES Differentiation in GSCs
(A) Western blot analysis of phosphorylated p65 (ser 536), total p65, phosphoryla
(B and C) Western blot analysis using indicated antibodies was performed on GS
(D) Box plots of normalized expression of STAT3,CEBPB, TAZ, and NF-kBmetag
sets as indicated are shown. Boxes show median 25th and 75th percentiles, wh
individual points. p value was determined using a nonparametric Wilcoxon test. F
and targets (see Supplemental Experimental Procedures) was condensed into a
significance.
(E) Time course western blot analysis of indicated antibodies after TNF-a treatm
treatment is shown.
(F) qRT-PCR analysis of MES signature master TFs STAT3, CEBPB, and TAZ in
adenovirus is shown. Error bar indicates ± SD. t test was used for statistical sign
(G) qRT-PCR analysis of YKL40 and CD44 after knockdown of all three master TF
72 hr prior to treatment with TNF-a for an additional 24 hr. Error bar indicates ±
See also Figure S6.
342 Cancer Cell 24, 331–346, September 9, 2013 ª2013 Elsevier Incwe show that in newly diagnosed GBM, an increasedMESmeta-
gene, CD44 expression, or NF-kB activation is associated with
poor radiation response and shorter survival even in the absence
of IDH1 mutation. Although NF-kB has been previously impli-
cated in GBM (Bredel et al., 2006, 2011; Park et al., 2009), our
studies identify a role for NF-kB in mediating radiation resis-
tance. We speculate that global MES differentiation induced by
NF-kB parallels activation of checkpoint pathways, leading to
enhanced DNA damage repair and unperturbed cell cycle pro-
gression in response to IR. Moreover, given that NF-kB has
been shown to mediate antiapoptotic effects and DNA damage
repair (Magne´ et al., 2006), it is conceivable that this pathway
acts as a potential link between MES differentiation and radio-
resistance. In the context of previous studies showing that the
CD133+ GSCs are resistant to radiation (Bao et al., 2006), and
even more efficiently under the influence of the brain microenvi-
ronment (Jamal et al., 2012), it remains to be seen whether
CD133+ subpopulation within the CD44high GSCs represents a
refinement of the radioresistant cell types.
In summary (Figure 8B), we show that although GBM patient
tumors appear predominantly MES/CIMP at presentation or
progression, the GSCs derived from these tumors using a stan-
dard isolation procedure tend to be PN/CIMP+ (despite absence
of the IDH1 mutation), suggesting that tumor microenviron-
mental factors in humans may induce a MES/CIMP signature.
We further show that in a subset of the PN/CIMP GSCs, MES
differentiation with associated enrichment of CD44-expressing
subpopulations and radioresistance can be induced in an
NF-kB-dependent fashion. Our data suggest that inhibition of
NF-kB activation can directly affect radioresistance and pre-
sents an attractive therapeutic target for GBM.EXPERIMENTAL PROCEDURES
GSCs Isolation and Cell Culture
Freshly resected tumor tissues were enzymatically and mechanically dissoci-
ated into single cells and grown in DMEM/F12 media supplemented with B27
(Invitrogen), EGF (20 ng/ml), and bFGF (20 ng/ml). After 2 to 4 weeks, free-
floating neurospheres were collected and thereafter routinely cultured in the
above-mentioned neurosphere media, with dissociation to single cells every
5–6 days. For growth factor comparison, PDGF (R&D Systems) was used at
a final concentration of 10 ng/ml. For cytokine treatment, GSCs were dissoci-
ated into single cells with Accutase (Sigma Aldrich) and treated with various
concentrations and durations as indicated in figure legends. IL-6, IL-8, IL-10,
and TGF-b were obtained from R&D Systems, and TNF-a was from Sigmated STAT3 (Tyr 705), STAT3, and C/EBPb in GSCs is shown.
C23 (B) and 11 (C) sorted for CD44high or CD44low subpopulations.
ene inCD44low (green boxes) orCD44high (red boxes) tumors frommultiple data
ile whiskers represent the 5th and the 95th percentiles. Outliers are shown as
or the NF-kB metagene, the average expression of 38 NF-kB family members
metagene and plotted. Wilcoxon signed-rank test was used to test statistical
ent in GSC11 transduced with RFP or IkB-SR adenovirus 24 hr prior to TNF-a
GSC11 treated with TNF-a with or without pretreatment with RFP or IkB-SR
ificance. *p < 0.05 and **p < 0.005.
s (STAT3, C/EBPb, and TAZ) in GSC11 is shown. Cells were treated with siRNA
SD. t test was used for statistical significance. *p < 0.05 and **p < 0.005.
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Figure 7. MES Differentiation, CD44 Levels, and NF-kB Activation Are Predictive of Radiation Response in GBM
(A) Representative MRI scans of postoperative/pre-RT and post-RT responses of patients typically classified as responders or nonresponders are shown.
(B) Box plots show the proportion of patients classified as responders or nonresponders against the PN/MES metagene quartiles in all newly diagnosed GBM
cases (n = 149). Chi-square test was used to assess statistical significance.
(C) Box plot is shown for IDH1 WT cases (n = 121).
(D) Kaplan Meier curves show survival of newly diagnosed patients based on PN/MES metagene scores. Low MES represents the bottom one-third of the cases
whereas high MES was the top two-thirds. Log rank test was used to assess statistical significance.
(E) Kaplan Meier curves showing survival of newly diagnosed GBM-IDH1 WT patients based on PN/MES metagene scores.
(F–L) Bar graph shows the proportion of OLIG2 (F), CD44 (G), p-p65 (J), and COX2 (K) expression in newly diagnosed GBM-IDH1 WT patients classified as
radiation responders or nonresponders. Proportions of patients who responded or did not respond were compared using chi-square test. Kaplan Meier curves
show survival of newly diagnosed GBM-IDH1 WT patients based on OLIG2 (H), CD44 (I), and COX2 (L).
See also Figure S7 and Tables S6–S8.
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NFkB Activation and Radiation Resistance in GBMAldrich. RFP and IkB-SR adenovirus were obtained from Vector Biolabs. The
use of human tumor tissue samples and all other tumor-related studies were
conducted in accordance with the protocols approved by the Institutional
Review Board at the UT, M.D. Anderson Cancer Center, or the Medical Ethical
Committee at the University Medical Center Groningen. The use of the tissues
for the experiments involving isolation of GSCs, DNA andRNA isolation, and/or
IHC on human tumors was exempt from requiring consent as per the MDACCCaInstitutional Review Board. Patient materials at UMCG were obtained after
routine diagnostics, coded according to the National Code for the Good Use
of Patient Material, and were exempt from informed consent.
Microarray and Bioinformatic Analyses
RNA labeling and hybridization to Affymetrix HGU133 version 2.0 gene-
chips was performed by Expression Analysis (Durham, NC). Raw .cel filesncer Cell 24, 331–346, September 9, 2013 ª2013 Elsevier Inc. 343
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Figure 8. Features Associated with MES Differentiation Induced by NF-kB in GBM
(A) Consecutive 5 mmsections were stained for variousmarkers by IHC. Two independent areaswithin a same tumor are shown formutual exclusive expression of
OLIG2 from CD44, p-p65, and IBA. Scale bar: 100 mm.
(B) Cartoon shows a summary of our findings. We propose that GSCs when isolated from the microenvironment may differ in their molecular signatures from the
parental tumor. Whereas GBMs at the extreme ends of the PN/MES axis will likely contain (and enrich for) GSCs with similar signatures to the parental tumor,
GBMswith intermediate to high MES signatures enrich for PN GSCs that are maintained in a MES state in the human tumor microenvironment (by cell types such
as macrophages/microglia). These PN GSCs also tend to be CIMP+ although derived from G-CIMP tumors that lack the IDH1 mutation. MES differentiation,
CD44 enrichment, and radioresistance can be induced in PN/CIMP GSCs by activation of NF-kB and downstream master TFs (STAT3, C/EBPb, and TAZ). In
contrast, MES GSCs are CIMP, predominantly express CD44, are radioresistant, and exhibit constitutive activation of NF-kB and downstream master TFs.
See also Table S9.
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Cancer Cell
NFkB Activation and Radiation Resistance in GBM(GSE49009) were processed using R and Bioconductor (Gentleman et al.,
2004), using a custom CDF (Sandberg and Larsson, 2007), with background
correction, log transformation, and quantile normalization performed using
the RMA algorithm. Detailed description of all other bioinformatic analyses is
described in Supplemental Experimental Procedures.
Xenograft Models and Treatments
GSCs were implanted intracranially using the guide screw system in 4- to
5-week-old NOD/SCID or Foxn1nu mice. After 1 week of guide screw implan-
tation, 53 105 cells or fewer (as indicated) were injected intracranially in each
mouse and randomly distributed between groups. Aminimum of fivemice was
used in each group. For in vivo bioluminescent imaging, GSCs were engi-
neered to express luciferase by transducing with pCignal lenti-CMV-luc viral
particles (SABiosciences). Kinetics of tumor growth was monitored using
IVIS 200 system bioluminescent imaging and tumor volume measured using
Living Image 4.1 software. IR was delivered using fractionated doses
(2.5 Gy 3 4) using a 60Co teletherapy unit and a custom gig with validated
dosimetry. Mice that presented neurological symptoms (i.e., hydrocephalus,
seizures, inactivity, and/or ataxia) or that were moribund were sacrificed,
and brains were fixed in formalin, stained with H&E to confirm the presence
of tumor, and subject to IHC. All animal procedures were reviewed and
approved by the Institutional Animal Care and Use Committee at the
M.D. Anderson Cancer Center.
ACCESSION NUMBERS
The Gene Expression Omnibus accession number for the microarray experi-
ments is GSE49009.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and nine tables and can be found with this article online at
http://dx.doi.org/10.1016/j.ccr.2013.08.001.
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